Introduction
Leukemia is the most common childhood malignancy, and Bprecursor ALL is the most prevalent phenotype. The treatment of childhood ALL has improved dramatically over the past several decades with 5-year event-free survival rates of 20% in the early 1970s as compared to 70-75% in the 1990s. 1 The outcome for the 25-30% of children who relapse remains very poor. 2 Agents that target B-lineage leukemia cells are needed to improve survival for children who have refractory or relapsed disease. There are no monoclonal antibodies (Mabs) conjugated to toxins (immunotoxins or ITs) which are currently being evaluated in clinical trials for children with Blineage leukemia. Mabs directed against the cell surface antigens, CD19 and CD22, conjugated to dgRTA via a stable thiol-containing linker (SMPT) have been used in phase I trials in over 75 adult patients with B-lineage NHL. [3] [4] [5] [6] [7] [8] These ITs are also cytotoxic to leukemia blasts obtained from children with B-precursor ALL. 9 These ITs have never been evaluated for efficacy in leukemia in an in vivo setting. The purpose of this study was to extend our previous work of testing these agents in vitro on B-precursor leukemia cells, and to determine the efficacy of the anti-CD19 and anti-CD22 ITs separately, and in combination, in SCID mice with a B-precursor ALL cell line, NALM-6-UM1.
Materials and methods

NALM-6-UM1 cells
The human NALM-6-UM1 pre-B ALL cell line obtained from ATCC was maintained by serial passages in RPMI-1640 medium (GIBCO Laboratories, Grand Island, NY, USA) containing 25 mM Hepes buffer, 10% heat-inactivated fetal bovine serum (FBS), 100 units/ml penicillin, 100 g/ml streptomycin and 100 M glutamine. The cells were grown in a humidified atmosphere of 5% CO 2 and air and expanded every other day. Prior to injection into SCID mice, cells were washed once and then re-suspended in filter-sterilized phosphate-buffered saline (PBS). Mice received 5 × 10 6 cells via the dorsal tail vein.
SCID mice
Male SCID mice (CB-17 SCID/SCID) originated from Dr Mel Bosma's colony at Fox Chase Cancer Center (Philadelphia, PA, USA) and were obtained from both the Carolinas Medical Center and Taconic Laboratories (Germantown, NY, USA). They were housed and maintained in a specific pathogen-free (SPF) facility. They were given autoclaved food and sterile water ad libitum, and all manipulations were performed in a laminar flow hood.
SCID/NALM-6-UM1 mice
Ten-to thirteen-week-old SCID mice weighing 25 to 30 g received 150 cGy of total body irradiation from a Cesium source (JL Shepherd Model 143 Irradiator) 24 h prior to tumor cell inoculation. The mice were inoculated via the tail vein with 5 × 10 6 NALM-6-UM1 cells, and then monitored daily. They were killed at the onset of weakness or paralysis of either front or back legs, a clinical symptom that often preceded death. Necropsy and PCR amplification for the human ␤-globin gene were performed using tissue from the brain, liver, spleen, bone marrow, heart, lung, testes and kidney.
Immunotoxins
ITs were prepared as previously described. 10 Mabs used to prepare the ITs are obtained from hybridoma cells secreting either the mouse IgG 1 anti-CD19 (HD37) 10, 11 or the anti-CD22 (RFB4) Mabs.
12, 13 The dgRTA was prepared in a good laboratory practice (GLP) scale-up laboratory from lots of ricin extracted from castor beans (Browning Seed Company, Plainview, TX, USA). The crosslinking agent 4-succinimidyl-oxycarbonyl-␣-methyl-␣-(2-pyridildithio) toluene (SMPT) was used to conjugate the Mab to the dgRTA.
Determination of LD 50 of the ITs in mice
The LD 50 of HD37-dgRTA and RFB4-dgRTA as well as an irrelevant control IT against CD25 (RFT5-dgRTA) were determined by injecting groups of mice with escalating doses of the ITs. The LD 50 for each agent was identical to that previously determined in BALB/c mice. 14 
IT therapy of mice with early disease
IT therapy of mice with advanced disease
Advanced disease was defined as SCID mice inoculated with NALM-6-UM1 cells 2 weeks before treatment with the ITs. The ITs were administered in the same fashion as described for the mice with early disease.
Detection of human DNA in SCID mice
Human DNA was detected by amplifying a 110-bp fragment from the first exon of the human ␤-globin gene. Oligonucleotide primers (H3: 5Ј ACA CAA CTG TGT TCA CTA GC 3Ј and H4: CAA CTA CAT CCA CGT TCA CC 3Ј) were purchased from Integrated DNA Technologies (Coralville, IA, USA). Human DNA was amplified using 0.2-1.2 g genomic DNA with 2.5 U of Taq DNA polymerase (Promega, Madison, WI, USA) in 1 × PCR buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 50% glycerol and 1% Triton X-100) containing 0.74 g of each primer and 200 M/l dNTPs (Promega) in a total volume of 100 l. Before amplification, samples were overlaid with 100 l of mineral oil (Sigma, St Louis, MO, USA). Forty cycles were performed by incubating samples at 95°C for 1 min, 55°C for 1 min and 72°C for 90 s, and by extending the 72°C elongation step for 2 s after each cycle and for 10 min after 40 cycles. To detect the amplified DNA, 7 l aliquots of the PCR product were electrophoresed on a Multiphor II electrophoresis unit using Leukemia the CleanGel DNA Analysis Kit (Pharmacia Biotech, Uppsala, Sweden). The gels were stained in 0.00002% ethidium bromide solution and visualized with a UV transilluminator. Photographs of the gels were taken with a ChemiImager 4000 (Alpha Innotech Corp., San Leandro, CA, USA). The negative control PCR reaction mixture contained DNA from a SCID mouse which had not been inoculated with human ALL. The positive control PCR reaction mixture contained DNA from the NALM-6-UM1 pre-B ALL cell line. The assay is capable of detecting one tumor cell in 100 000 normal cells as determined by serial 1:10 dilutions of NALM-6-UM1 cells mixed with 3B3 mouse lymphoma cells.
Results
Development of a SCID/human Pre-B ALL model
To evaluate the efficacy of our ITs in an in vivo model of early and advanced disseminated disease, we used the NALM-6-UM1 pre-B ALL cell line. In pilot experiments, we challenged groups of four mice with an i.v. inoculum of either 5 × 10 5 or 1 × 10 7 cells. Half of the mice were irradiated with 150 cGy prior to injection with tumor cells. Forty-eight days later, all of the mice died of disseminated disease. The onset of paresis or paralysis was similar in both groups receiving either the high or low dose of cells, provided the mice were preirradiated (data not shown). Postmortem histopathology and immunohistochemistry were performed on tissue sections from various organs revealing diffuse leukemic infiltration.
Effect of ITs on the survival of mice with early disease
Mice were killed when they developed paresis or paralysis, and Kaplan-Meier plots were constructed from the data. Mice receiving saline or the control IT had a mean survival time of 36.5 and 30.8 days, respectively. HD37-dgRTA or RFB4-dgRTA extended the mean survival time to 67.5 and 65.5 days, respectively (P Ͻ 0.005). Treatment with Combotox resulted in a mean survival of 91.2 days (P = 0.0009) ( Figure  1 ). There was a total of eight long-term survivors (healthy
Figure 1
Survival of IT-treated SCID/human ALL mice with early disease. Pre-irradiated SCID mice were injected via tail vein with 5 × 10 6 NALM-6-UM1 cells 24 h prior to treatment. Mice received daily intraperitoneal injections of each IT at 40% of the LD 50 divided into four equal doses. In three separate experiments mice received either saline (n = 10), HD37-dgRTA (n = 14, P = 0.005), RFB4-dgRTA (n = 13, P = 0.001), Combotox (n = 14, P = 0.0009) or RFT5-dgRTA (control IT) (n = 6, P = 0.56). The percentage of mice surviving vs the number of days following inoculation is depicted. beyond 150 days) among the three groups. Because a single NALM-6-UM1 cell causes disseminated and fatal leukemia in SCID mice within 150 days, the long-term survival of ITtreated SCID mice challenged with 5 × 10 6 NALM-6-UM1 cells is consistent with у6 logs kill of NALM-6-UM1 cells in vivo with either IT.
Effect of ITs on the survival of mice with advanced disease
Mice receiving saline or the control IT had a mean survival time of 44.0 and 40.8 days, respectively. Mice that received HD37-dgRTA survived for a mean of 47.5 days. This was not significantly different from the saline-treated mice (P = 0.26). Those treated with RFB4-dgRTA had a mean survival time of 62.5 days (P = 0.002) where those mice receiving Combotox had a mean survival of 81.4 days (P = 0.02) (Figure 2 ). It is important to note that there were two long-term survivors in the group treated with Combotox.
A comparison of the results in mice with early and late disease demonstrate that treatment with HD37-dgRTA significantly prolonged survival only in mice with early disease, whereas treatment with either RFB4-dgRTA or 'Combotox' significantly prolonged survival in mice with either early or late disease ( Table 1) .
Effect of ITs on the leukemia cell burden
PCR amplification of a 110-bp DNA fragment from the first exon of the human ␤-globin gene was used to confirm the presence of human DNA in brain, liver, spleen, bone marrow, heart, lung, testes and kidney of the SCID/NALM-6-UM1 mice at the time of necropsy. The numbers of organs positive by PCR were greatest in the saline and control IT-treated groups as would be expected. Analysis of tissues from mice who eventually died of disease and were treated with HD37-
Figure 2
Survival of IT-treated SCID/human ALL mice with advanced disease. Pre-irradiated SCID mice were injected via tail vein with 5 × 10 6 NALM-6-UM1 cells 2 weeks prior to treatment. Mice received daily intraperitoneal injections of each IT at 40% of the LD 50 divided into four equal doses. In two separate experiments mice received either saline (n = 9), HD37-dgRTA (n = 10, P = 0.26), RFB4-dgRTA (n = 10, P = 0.002), Combotox (n = 9, P = 0.02) or RFT5-dgRTA (control IT) (n = 10, P = 0.31). The percentage of mice surviving vs the number of days following inoculation is depicted. dgRTA or RFB4-dgRTA showed a marked reduction in leukemic burden as determined by a negative PCR reaction. Mice receiving 'Combotox' had the fewest organs positive by PCR. There were also eight long-term survivors that were treated when they had early disease; one in the HD37-dgRTA group, three in the RFB4-dgRTA group, and four in the 'Combotox' group. There were two long-term survivors with advanced disease; both of which received treatment with 'Combotox'. PCR analysis of the organs from the survivors revealed no evidence of human leukemia cells (Table 2) .
Discussion
Other ITs, namely B43 anti-CD19-pokeweed anti-viral protein (PAP), have demonstrated in vivo antileukemic efficacy. 15 B4 anti-CD19-blocked ricin, also demonstrated efficacy in a SCID/NALM-6-UM1 tumor model. 16 Ricin A chain containing ITs have previously been determined to be cytotoxic to the NALM-6-UM1 cell line in vitro. 10 Approximately one-third of adult patients with B-lineage NHL treated with murine Mab-based ITs developed human anti-mouse antibodies (HAMA) or human anti-conjugate antibodies (HACA). 3, 4, 6 Despite this, patients have been retreated and objective responses have been observed. Our ITs did not cause hepatotoxicity in phase I trials in adults with B-lineage NHL. Vascular leak syndrome (VLS) was the dose-limiting toxicity. A retrospective analysis of the phase I trials revealed that VLS was most severe in patients who had undergone prior irradiation or who had no circulating tumor cells (CTCs). When these patients were excluded from the analysis, the maximum tolerated dose (MTD) had not been reached in any of the trials. 17 Another criticism of the immunoconjugate is its large size (180 kDa) and the decreased ability to penetrate large tumor masses when compared to smaller molecules. 18 Children with B-lineage leukemia represent a very different population of patients. The potential for using these ITs to effectively treat leukemia in children has not been determined. Leukemia cells should be more accessible to ITs. Children with leukemia have healthier organ systems, and are unlikely to have received prior irradiation, but do have CTCs. Hence, VLS should be mild. Their immune system is adversely affected by their disease and prior chemotherapy decreasing the likelihood of developing neutralizing antibodies.
The CD19 antigen is specific to the B-lineage lymphocytes and is not expressed on non-lymphohematopoietic tissues. 19 It is expressed on the majority of pre-B ALL blasts. It undergoes internalization upon binding to an anti-CD19 Mab. The CD19 molecule expressing the HD37 epitope is present on a mean Table 2 Effect of immunotoxins on organ involvement
Organ Treatment The table depicts the percentage of SCID/human ALL mice whose organs were positive by PCR analysis for the human ␤-globin gene. The mice received saline (n = 19), HD37-dgRTA (n = 24), RFB4-dgRTA (n = 23), Combotox (n = 23), or RFT5-dgRTA (n = 13). of 80% of B-precursor ALL blasts. 9 The CD22 molecules expressing the RFB4 epitope are present on approximately 50% of B-precursor ALL blasts. 9 The CD22 antigen is also specific to B-lineage lymphocytes and it undergoes rapid internalization and is expressed on the cells from 51% of children diagnosed with pre-B ALL. 20 The effect of our ITs separately or in combination had not been previously investigated in SCID mice with disseminated leukemia, although they had been thoroughly evaluated in the SCID/Daudi lymphoma model. 7, 14, 21 Previous studies performed in our laboratory showed that both HD37-dgRTA and RFB4-dgRTA are specifically cytotoxic to primary B-precursor ALL cells obtained from children newly diagnosed with ALL. 9 Both ITs resulted in a significant reduction in the number of viable leukemia cells, and the combination ('Combotox') was more effective. In our experiments we used the human NALM-6-UM1 cell line which has been used extensively by other investigators because it is extremely aggressive and capable of causing disseminated disease. 15 This cell line has undergone antigenic drift over time, and may therefore not be representative of leukemic blasts obtained from patients. Nonetheless, because it grows easily in culture and can be engrafted into SCID mice, it has served as a model for testing various antileukemia agents. The present work was undertaken to determine the in vivo anti-tumor activity of our ITs both separately and in combination.
Our results indicate that treatment with both HD37-dgRTA and RFB4-dgRTA resulted in significantly improved overall survival. This is consistent with results obtained in the in vitro testing of these agents, and may reflect the high expression of both molecules on the surface of NALM-6-UM1 cell line. The combination of the two ITs was more effective when administered together, also in accordance with our prior studies using lymphoblasts obtained from children with B-lineage ALL. The extent of organ involvement as determined by PCR analysis was markedly decreased by the treatments, especially in mice receiving 'Combotox'. Despite this, a substantial percentage of organs from mice with advanced disease was positive by PCR analysis. This suggests that these agents might best be used in relapsed patients when there is still evidence of limited disease. The marked reduction of disease in all of the organs as a result of treatment suggests that these agents are capable of penetrating organs and immunologically privileged and/or inaccessible sites such as CNS and testes. Although these Leukemia agents are most effective in targeting circulating tumor cells, the ability to penetrate sites where non-circulating tumor cells are present may have clinical utility in the setting of relapsed disease. The enhanced survival in early disseminated disease vs advanced disease may reflect the ability of the ITs to target circulating tumor cells before they enter tissue spaces to develop metastatic disease. A more likely explanation for the enhanced survival for the early disease model is the smaller tumor burden when compared to that at 14 days prior to the initiation of treatment. Both RFB4-dgRTA and Combotox were effective in the treatment of both early and advanced disease whereas treatment with HD37-dgRTA alone did not significantly prolong survival of the mice with advanced disease. This is also consistent with the increased potency of RFB4-dgRTA in vitro testing in other cell lines. 22 Importantly, eight mice with early disease and two with advanced disease were cured of their disease as determined by a negative PCR result of all organs harvested on day 150. Six had received treatment with 'Combotox', in accordance with the prediction that ITs will be more effective in the treatment of MRD. Our experiments demonstrate that leukemia may be amenable to treatment with these ITs.
In conclusion, these ITs are effective in significantly prolonging the life of SCID/human pre-B ALL mice. ITs are more effective when combined. Based on these results and the previously reported anti-leukemic efficacy of HD37-dgRTA and RFB4-dgRTA against actual lymphoblasts obtained from patients, we will next test Combotox in children with relapsed B-lineage ALL. The potency of these agents may allow for their combination with conventional chemotherapy up-front, and their specificity may allow for the treatment of patients with minimal residual disease. Future laboratory experiments combining these ITs with chemotherapy in the setting of leukemia are planned.
